Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Phibro Animal Health (PAHC), McKesson (MCK) and Boston Scientific (BSX)

Tipranks - Fri Feb 6, 5:54AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phibro Animal Health (PAHCResearch Report), McKesson (MCKResearch Report) and Boston Scientific (BSXResearch Report).

Claim 50% Off TipRanks Premium

Phibro Animal Health (PAHC)

Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Phibro Animal Health yesterday and set a price target of $32.00. The company’s shares closed last Wednesday at $41.00.

According to TipRanks.com, Ryskin is a 4-star analyst with an average return of 4.4% and a 56.2% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Phibro Animal Health has an analyst consensus of Hold, with a price target consensus of $42.33.

See Insiders’ Hot Stocks on TipRanks >>

McKesson (MCK)

Bank of America Securities analyst Allen Lutz reiterated a Buy rating on McKesson today and set a price target of $970.00. The company’s shares closed last Wednesday at $822.00.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 12.9% and a 66.9% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Hims & Hers Health, and Envista Holdings. ;'>

Currently, the analyst consensus on McKesson is a Strong Buy with an average price target of $957.91, a 13.4% upside from current levels. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $945.00 price target.

Boston Scientific (BSX)

Bank of America Securities analyst Travis Steed reiterated a Buy rating on Boston Scientific today and set a price target of $105.00. The company’s shares closed last Wednesday at $75.50.

According to TipRanks.com, Steed is a 4-star analyst with an average return of 6.6% and a 58.9% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Bausch + Lomb Corporation. ;'>

Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $114.31, implying a 40.5% upside from current levels. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.